Alemany A, Perez-Zsolt D, Raïch-Regué D et al. Cetylpyridinium Chloride Mouthwash to Reduce Shedding of Infectious SARS-CoV-2: A Double-Blind Randomised Clinical Trial. J Dent Res 2022; DOI: 10.1177/00220345221102310. Online ahead of print.
A 0.07% CPC mouthwash was associated with a significant increase of nucleocapsid protein levels in saliva, indicating enhanced disruption of viral particles.
This was a multi-centre, double-blind, placebo-controlled trial to assess the virucidal activity of cetylpyridinium chloride (CPC) mouthwashes. Outpatients who tested positive for SARS-CoV-2 infection with or without symptoms were randomised to perform washes and gargles for one minute with 15 mL of either coloured distilled water or 0.07% CPC mouthwash. The study outcomes were the SARS-CoV-2 log10 viral RNA load and the nucleocapsid protein levels, both in saliva at 1 and 3 hr after the intervention. In total, 118 patients were enrolled and randomised. The assessment of the viral load showed no significant differences between groups. The levels of SARS-CoV-2 nucleocapsid protein of lysed viruses were significantly higher in the CPC group. In non-hospitalised patients with asymptomatic or mild symptomatic SARS-CoV-2 infection, a 0.07% CPC mouthwash, compared to placebo, was associated with a significant increase of nucleocapsid protein levels in saliva, indicating enhanced disruption of viral particles.
About this article
Cite this article
Wadia, R. CPC for COVID patients. Br Dent J 233, 122 (2022). https://doi.org/10.1038/s41415-022-4517-y